{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T18:20:37Z","timestamp":1794075637608,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-55442-0","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T13:48:56Z","timestamp":1736171336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A 15-Item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-5825","authenticated-orcid":false,"given":"Tien","family":"Dam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-3145","authenticated-orcid":false,"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6549-4038","authenticated-orcid":false,"given":"John","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-5064","authenticated-orcid":false,"given":"Adam L.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Golbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4824-646X","authenticated-orcid":false,"given":"Samantha","family":"Budd Haeberlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the AL-108-231, PROSPERA, and 4RTNI investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"55442_CR1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","volume":"16","author":"AL Boxer","year":"2017","unstructured":"Boxer, A. L. et al. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 16, 552\u2013563 (2017).","journal-title":"Lancet Neurol."},{"key":"55442_CR2","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1212\/01.WNL.0000052991.70149.68","volume":"60","author":"U Nath","year":"2003","unstructured":"Nath, U., Ben-Shlomo, Y., Thomson, R. G., Lees, A. J. & Burn, D. J. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 60, 910\u2013916 (2003).","journal-title":"Neurology"},{"key":"55442_CR3","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/brain\/awh488","volume":"128","author":"DR Williams","year":"2005","unstructured":"Williams, D. R. et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson\u2019s syndrome and PSP-parkinsonism. Brain 128, 1247\u20131258 (2005).","journal-title":"Brain"},{"key":"55442_CR4","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1093\/brain\/124.7.1438","volume":"124","author":"U Nath","year":"2001","unstructured":"Nath, U. et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 124, 1438\u20131449 (2001).","journal-title":"Brain"},{"key":"55442_CR5","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/S0140-6736(99)04137-9","volume":"354","author":"A Schrag","year":"1999","unstructured":"Schrag, A., Ben-Shlomo, Y. & Quinn, N. P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354, 1771\u20131775 (1999).","journal-title":"Lancet"},{"key":"55442_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/WCO.0b013e32833be924","volume":"23","author":"DW Dickson","year":"2010","unstructured":"Dickson, D. W., Ahmed, Z., Algom, A. A., Tsuboi, Y. & Josephs, K. A. Neuropathology of variants of progressive supranuclear palsy. Curr. Opin. Neurol. 23, 394\u2013400 (2010).","journal-title":"Curr. Opin. Neurol."},{"key":"55442_CR7","doi-asserted-by":"publisher","first-page":"134919","DOI":"10.1016\/j.neulet.2020.134919","volume":"731","author":"L VandeVrede","year":"2020","unstructured":"VandeVrede, L., Boxer, A. L. & Polydoro, M. Targeting tau: Clinical trials and novel therapeutic approaches. Neurosci. Lett. 731, 134919 (2020).","journal-title":"Neurosci. Lett."},{"key":"55442_CR8","unstructured":"FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient\u2019s Voice in Medical Product Development and Regulatory Decision Making, <https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical> (2024)."},{"key":"55442_CR9","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/brain\/awm032","volume":"130","author":"LI Golbe","year":"2007","unstructured":"Golbe, L. I. & Ohman-Strickland, P. A. A clinical rating scale for progressive supranuclear palsy. Brain 130, 1552\u20131565 (2007).","journal-title":"Brain"},{"key":"55442_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","volume":"13","author":"AL Boxer","year":"2014","unstructured":"Boxer, A. L. et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial. Lancet Neurol. 13, 676\u2013685 (2014).","journal-title":"Lancet Neurol."},{"key":"55442_CR11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","volume":"27","author":"T Dam","year":"2021","unstructured":"Dam, T. et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat. Med 27, 1451\u20131457 (2021).","journal-title":"Nat. Med"},{"key":"55442_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","volume":"20","author":"GU H\u00f6glinger","year":"2021","unstructured":"H\u00f6glinger, G. U. et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol. 20, 182\u2013192 (2021).","journal-title":"Lancet Neurol."},{"key":"55442_CR13","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1212\/NXI.0000000000000266","volume":"3","author":"D Apetauerova","year":"2016","unstructured":"Apetauerova, D. et al. CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial. Neurol. Neuroimmunol. Neuroinflamm 3, e266 (2016).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"55442_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.clineuro.2016.04.021","volume":"146","author":"L Leclair-Visonneau","year":"2016","unstructured":"Leclair-Visonneau, L. et al. Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin. Neurol. Neurosurg. 146, 35\u201339 (2016).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"55442_CR15","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00415-016-8169-1","volume":"263","author":"G Nuebling","year":"2016","unstructured":"Nuebling, G. et al. PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. J. Neurol. 263, 1565\u20131574 (2016).","journal-title":"J. Neurol."},{"key":"55442_CR16","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/mds.25824","volume":"29","author":"E Tolosa","year":"2014","unstructured":"Tolosa, E. et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov. Disord. 29, 470\u2013478 (2014).","journal-title":"Mov. Disord."},{"key":"55442_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.parkreldis.2016.04.014","volume":"28","author":"J Bang","year":"2016","unstructured":"Bang, J. et al. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat. Disord. 28, 41\u201348 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"55442_CR18","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/mds.26580","volume":"31","author":"M Stamelou","year":"2016","unstructured":"Stamelou, M. et al. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. Mov. Disord. 31, 742\u2013747 (2016).","journal-title":"Mov. Disord."},{"key":"55442_CR19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/mdc3.13010","volume":"7","author":"LI Golbe","year":"2020","unstructured":"Golbe, L. I., Ohman-Strickland, P., Beisser, E. B. & Elghoul, F. T. A convenient prognostic tool and staging system for progressive supranuclear palsy. Mov. Disord. Clin. Pr. 7, 664\u2013671 (2020).","journal-title":"Mov. Disord. Clin. Pr."},{"key":"55442_CR20","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/mds.28470","volume":"36","author":"MT Gr\u00f6tsch","year":"2021","unstructured":"Gr\u00f6tsch, M. T. et al. A modified progressive supranuclear palsy rating scale. Mov. Disord. 36, 1203\u20131215 (2021).","journal-title":"Mov. Disord."},{"key":"55442_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/mds.27964","volume":"35","author":"I Piot","year":"2020","unstructured":"Piot, I. et al. The progressive supranuclear palsy clinical deficits scale. Mov. Disord. 35, 650\u2013661 (2020).","journal-title":"Mov. Disord."},{"key":"55442_CR22","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/mds.28991","volume":"37","author":"AM Wills","year":"2022","unstructured":"Wills, A. M. et al. A modified progressive supranuclear palsy rating scale for virtual assessments. Mov. Disord. 37, 1265\u20131271 (2022).","journal-title":"Mov. Disord."},{"key":"55442_CR23","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.10583","volume":"18","author":"A Schrag","year":"2003","unstructured":"Schrag, A. et al. Health-related quality of life in patients with progressive supranuclear palsy. Mov. Disord. 18, 1464\u20131469 (2003).","journal-title":"Mov. Disord."},{"key":"55442_CR24","first-page":"5283259","volume":"2017","author":"L Wiblin","year":"2017","unstructured":"Wiblin, L., Durcan, R., Lee, M. & Brittain, K. The importance of connection to others in QoL in MSA and PSP. Parkinsons Dis. 2017, 5283259 (2017).","journal-title":"Parkinsons Dis."},{"key":"55442_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.sleep.2016.05.002","volume":"22","author":"CM Walsh","year":"2016","unstructured":"Walsh, C. M. et al. Rest-activity rhythm disruption in progressive supranuclear palsy. Sleep. Med 22, 50\u201356 (2016).","journal-title":"Sleep. Med"},{"key":"55442_CR26","doi-asserted-by":"publisher","unstructured":"Walsh, C. M. et al. Sleepless night and day, the plight of progressive supranuclear palsy. Sleep 40 https:\/\/doi.org\/10.1093\/sleep\/zsx154 (2017).","DOI":"10.1093\/sleep\/zsx154"},{"key":"55442_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.parkreldis.2021.10.007","volume":"92","author":"J Jaeger","year":"2021","unstructured":"Jaeger, J. et al. Development of a cognitive composite for measuring change in progressive supranuclear palsy. Parkinsonism Relat. Disord. 92, 94\u2013100 (2021).","journal-title":"Parkinsonism Relat. Disord."},{"key":"55442_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.parkreldis.2018.08.025","volume":"60","author":"C Brittain","year":"2019","unstructured":"Brittain, C. et al. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism Relat. Disord. 60, 138\u2013145 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"55442_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/mdc3.12243","volume":"3","author":"DA Hall","year":"2016","unstructured":"Hall, D. A. et al. Clinimetric analysis of the motor section of the progressive supranuclear palsy rating scale: Reliability and factor analysis. Mov. Disord. Clin. Pr. 3, 65\u201367 (2016).","journal-title":"Mov. Disord. Clin. Pr."},{"key":"55442_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/mds.26809","volume":"32","author":"S Koga","year":"2017","unstructured":"Koga, S. et al. Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Mov. Disord. 32, 246\u2013255 (2017).","journal-title":"Mov. Disord."},{"key":"55442_CR31","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awq158","volume":"133","author":"RG Brown","year":"2010","unstructured":"Brown, R. G. et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 133, 2382\u20132393 (2010).","journal-title":"Brain"},{"key":"55442_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/13803395.2019.1572073","volume":"41","author":"K Duff","year":"2019","unstructured":"Duff, K., McDermott, D., Luong, D., Randolph, C. & Boxer, A. L. Cognitive deficits in progressive supranuclear palsy on the repeatable battery for the assessment of neuropsychological status. J. Clin. Exp. Neuropsychol. 41, 469\u2013475 (2019).","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"55442_CR33","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord. 32, 853\u2013864 (2017).","journal-title":"Mov. Disord."},{"key":"55442_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/jamaneurol.2019.4347","volume":"77","author":"E Jabbari","year":"2020","unstructured":"Jabbari, E. et al. Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome. JAMA Neurol. 77, 377\u2013387 (2020).","journal-title":"JAMA Neurol."},{"key":"55442_CR35","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1093\/brain\/awad105","volume":"146","author":"D Street","year":"2023","unstructured":"Street, D. et al. Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials. Brain 146, 3232\u20133242 (2023).","journal-title":"Brain"},{"key":"55442_CR36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaneurol.2023.0488","volume":"80","author":"L VandeVrede","year":"2023","unstructured":"VandeVrede, L. et al. Evaluation of plasma phosphorylated tau217 for differentiation between alzheimer disease and frontotemporal lobar degeneration subtypes among patients with corticobasal syndrome. JAMA Neurol. 80, 495\u2013505 (2023).","journal-title":"JAMA Neurol."},{"key":"55442_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.parkreldis.2020.08.021","volume":"79","author":"AE Lang","year":"2020","unstructured":"Lang, A. E. et al. The Cortical basal ganglia functional scale (CBFS): Development and preliminary validation. Parkinsonism Relat. Disord. 79, 121\u2013126 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"55442_CR38","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1212\/WNL.0000000000003305","volume":"87","author":"S Dutt","year":"2016","unstructured":"Dutt, S. et al. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology 87, 2016\u20132025 (2016).","journal-title":"Neurology"},{"key":"55442_CR39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1098214005283748","volume":"27","author":"DR Thomas","year":"2006","unstructured":"Thomas, D. R. A general inductive approach for analyzing qualitative evaluation data. Am. J. Eval. 27, 237\u2013246 (2006).","journal-title":"Am. J. Eval."},{"key":"55442_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/104973239500500201","volume":"5","author":"JM Morse","year":"1995","unstructured":"Morse, J. M. The significance of saturation. Qual. Health Res 5, 147\u2013149 (1995).","journal-title":"Qual. Health Res"},{"key":"55442_CR41","doi-asserted-by":"crossref","unstructured":"Andrich, D. Rasch Models for Measurement. (Sage Publications, New York City, 1988)","DOI":"10.4135\/9781412985598"},{"key":"55442_CR42","unstructured":"Brown, T. A. Confirmatory factor analysis for applied research. (The Guilford Press, New York City, 2006)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55442-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55442-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55442-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T14:03:24Z","timestamp":1736172204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55442-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55442"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55442-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"11 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tien Dam, Lili Yang, Colin Gillis, Yumeng Li, Barbara Kolb, and Samantha Budd Haeberlein are former employees of and may hold stock\/stock options in Biogen. John O\u2019Gorman is an employee of and may hold stock in Biogen. Adam Boxer receives research support from the National Institutes of Health, Tau Research Consortium, Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, Alzheimer\u2019s Drug Discovery Foundation, Alzheimer\u2019s Association, Biogen, Eisai, and Regeneron and has served as a consultant for AGTC, Alector, Arkuda, Arvinas, AviadoBio, AZTherapeutics, Boehringer Ingelheim, GSK, Humana, Life Edit Therapeutics, Oligomerix, Roche, TrueBinding, and Wave. Lawrence Golbe has received research support from Biogen, travel support from CurePSP, and Consultant fees from AI Therapeutics, Amylyx, Apellis, Aprinoia, Ferrer, Mitochon, Roche, and UCB. These analyses were funded by Biogen (Cambridge, MA, USA). The 4 Repeat Tauopathy Imaging Initiative is funded by National Institutes of Health grant R01AG038791.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"414"}}